Shionogi Trial Explores New Front in Pompe Disease Fight

OSAKA, Japan – March 19, 2026 – Shionogi & Co., Ltd. has officially launched a new front in the battle against late-onset Pompe disease (LOPD), announcing the enrollment of the first patients in its global Phase 2 clinical trial, named Esprit. The study will evaluate an investigational oral drug, S-606001, as an add-on to the current standard of care, signaling a potential paradigm shift in how this rare and progressive genetic disorder is managed.

A Two-Pronged Attack on a Progressive Disease

Pompe disease is a relentless condition caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Without enough functional GAA, the body cannot effectively break down glycogen, a complex sugar, which then accumulates to toxic levels within the cells' lysosomes, particularly in muscle tissue. In its late-onset form, which affects roughly one in 22,000 people worldwide, this buildup causes progressive muscle weakness, severe respiratory complications, and a shortened lifespan.

For years, the primary treatment has been enzyme replacement therapy (ERT), which involves regular intravenous infusions of a manufactured version of the missing GAA enzyme. This approach, pioneered by companies like Sanofi, tackles the problem by trying to clear out the accumulated glycogen. While a life-altering intervention for many, ERT is not a cure, and its effectiveness can be limited.

Shionogi's S-606001 represents a fundamentally different strategy. As a substrate reduction therapy (SRT), it doesn't focus on clearing existing glycogen but rather on slowing its production. The oral drug works by inhibiting glycogen synthase (GYS1), the enzyme responsible for creating glycogen in the first place.

The Esprit trial is designed to test the hypothesis that attacking the problem from both sides—reducing glycogen production with S-606001 while simultaneously enhancing its breakdown with ERT—could lead to better outcomes than ERT alone. This dual-mechanism approach has generated significant excitement among researchers and patients who have long sought more comprehensive treatment options.

Addressing the Unmet Needs of a Resilient Community

The hope surrounding the Esprit trial stems from the well-documented limitations of existing treatments. While ERT can slow disease progression, many patients still experience a gradual decline in muscle strength and respiratory function over time. The therapy's efficacy can wane, and its bi-weekly intravenous administration poses a significant logistical and quality-of-life burden for patients and their families.

“The Pompe community is greatly appreciative of Shionogi’s commitment to developing new treatment options for people living with late-onset Pompe disease. Each person deserves alternatives to help them best manage their condition,” said Brad Crittenden, Chairman of the International Pompe Association and Executive Director of the Canadian Association of Pompe, in a statement.

The challenges for the Pompe community often begin long before treatment. The disease's rarity and its symptomatic overlap with other neuromuscular disorders frequently lead to a protracted and frustrating diagnostic odyssey. By the time a correct diagnosis is made, significant and often irreversible muscle damage may have already occurred. An oral therapy that could potentially enhance the standard of care, making it more effective and durable, could dramatically alter the long-term trajectory for individuals living with LOPD.

The Esprit study itself is a 52-week, randomized, placebo-controlled, double-blind trial that will enroll participants across the United States, European Union, and United Kingdom, reflecting a global effort to address this unmet need.

Shionogi's Strategic Foray into Rare Diseases

The initiation of the Esprit trial is more than just a single clinical milestone; it is a clear indicator of Shionogi's deepening strategic commitment to the rare disease sector. The 148-year-old Japanese pharmaceutical giant is methodically building a portfolio aimed at conditions with high unmet needs, moving into a specialized market where scientific innovation can command significant value.

Shionogi acquired the exclusive worldwide rights for S-606001 (previously known as MZE001) from Maze Therapeutics in 2024, an acquisition that now forms a cornerstone of its rare disease pipeline. The compound has already received both Orphan Drug Designation and a Rare Pediatric Disease Designation from the U.S. Food and Drug Administration, underscoring its potential significance.

This move is part of a broader pattern. The company is also advancing programs for other rare conditions like Fragile X syndrome and Jordan’s Syndrome. Furthermore, Shionogi has announced plans to acquire global rights to a treatment for amyotrophic lateral sclerosis (ALS), another devastating neurological disease. This strategy of acquiring and developing promising assets in the rare disease space positions Shionogi to become a more significant player in this highly competitive field.

“There is a significant unmet need for new treatment approaches that can be complementary to existing treatments to further slow disease progression,” noted Juan Carlos Gomez, M.D., Chief Medical Officer at Shionogi. “This is an important milestone for Shionogi, as we continue to expand our work in rare disease, and we hope it will prove to be an important step forward for the Pompe community.”

A Crowded Field of Innovation

Shionogi is not entering this field in a vacuum. The pursuit of better Pompe disease treatments has spurred a wave of innovation across the biopharmaceutical industry, creating a dynamic and competitive landscape. The market has already seen the arrival of next-generation ERTs, such as Sanofi’s Nexviazyme and Amicus Therapeutics' two-part therapy, Pombiliti and Opfolda, both designed to improve upon the original enzyme replacement model.

Further on the horizon is the promise of gene therapy. Companies like Spark Therapeutics and Astellas Pharma are developing treatments that aim to provide a durable, one-time fix by delivering a functional copy of the GAA gene directly to the body's cells, allowing them to produce their own enzyme.

Even within the substrate reduction space, Shionogi faces competition. Aro Biotherapeutics, for instance, is developing ABX1100, which also targets the GYS1 enzyme but uses a different mechanism known as siRNA (small interfering RNA). The fact that multiple companies are converging on GYS1 as a therapeutic target validates the scientific rationale behind this approach. While S-606001's journey is just beginning, its progress in the Esprit trial will be watched closely by patients, physicians, and competitors alike, as it represents a key test for a novel strategy that could one day become a vital part of the standard of care for Pompe disease.